Fast-Growing Ipsen Is Looking For More Acquisitions
The specialist pharma company is looking to expand further, and aims to add more to its in-house pipeline across neuroscience, oncology and rare diseases.
Scrip - July 30, 2026

Opella Backs Digestive Growth With $70m Mexico Probiotic Production Line
Opella has invested $70m in a new Enterogermina production line at its Ocoyoacac site in Mexico, adding 200m mini-bottles of annual capacity and functioning as a regional hub for the probiotic brand.
HBW Insight - July 30, 2026

Execs On The Move: July 20–24, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - July 30, 2026

Moving The Goalposts? FDA Issues Fresh PSGs For Peptides
Ahead of an anticipated slew of future generic competition for peptide products over the coming years, the FDA has published a fresh batch of 17 revised draft product-specific guidances.
Generics Bulletin - July 30, 2026

Texas AG Investigates Lip And Feminine Care Products For Potentially Deceiving Consumers
Texas Attorney General Ken Paxton says his office will investigate various lip and feminine care products, including brands marketed by Procter & Gamble and Kimberly-Clark, for potentially violating the Texas Deceptive Trade Practices Act.
HBW Insight - July 30, 2026

Clinical-Evidence Debate And Electrophysiology Rivals Cool Boston Scientific’s Hottest Franchises
A sharp US slowdown in Boston Scientific’s WATCHMAN LAAC franchise — driven by clinical-evidence debate hitting standalone referrals — and intensifying PFA competition in electrophysiology forced a full-year guidance cut, with management warning the pressure will persist into 2027.
Medtech Insight - July 30, 2026

Quotables: Pharma Leaders On The Month’s Hot Topics
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - July 30, 2026

Manufacturers To Pay Higher User Fees In FY 2027; FDA Raises Most Submission Fees Nearly 10%
The Food and Drug Administration will increase user fees for most medical device submissions by nearly 10% in FY 2027 under its annual MDUFA fee schedule, with the annual establishment registration fee rising nearly 21% from FY 2026.
Medtech Insight - July 30, 2026

GE HealthCare Posts Best Orders Quarter Since 2023 Spinoff, But Payoff Is Deferred To 2027
GE HealthCare posted its strongest orders quarter since its 2023 spinoff, with an 11.1% organic rise and a $23.9bn backlog, and flagged that much of the growth will convert to revenue in 2027.
Medtech Insight - July 30, 2026

Manufacturing Milestone Could Unlock Alvotech’s Stalled US Pipeline
The FDA’s VAI classification closes Alvotech’s Reykjavik inspection without formal enforcement, easing a major regulatory obstacle for several pending US biosimilar applications.
Generics Bulletin - July 30, 2026

Decline Accelerates For Biogen’s Biosimilars
Biogen’s biosimilars sales fell by 8% in the first half of 2026 – but that decline is only going to get steeper by the end of the year, according to the firm’s forecasts.
Generics Bulletin - July 30, 2026

Teva Lifts Risperidone Forecast Ahead Of Cautious Olanzapine Rollout
Teva has raised its 2026 Uzedy forecast after another quarter of strong growth, while warning that olanzapine revenues will build slowly as payer access develops and it assesses potential US generic-drug tariffs.
Generics Bulletin - July 30, 2026

Boston Scientific Cuts Guidance A Third Time, Plans $800m Restructuring
Boston Scientific beat Q2 estimates but cut full-year guidance and unveiled an $800m restructuring, as softness in its high-margin WATCHMAN and EP franchises pressures margins into 2027. Management is betting on a 2028 recovery led by interventional cardiology.
Medtech Insight - July 30, 2026

Sanofi’s Pipeline Reckoning Begins Under New CEO Garijo
Sanofi's Garijo has vowed deeper pipeline scrutiny following the amlitelimab discontinuation in atopic dermatitis.
Scrip - July 30, 2026

AI ‘Inspired By Quantum Physics’ Aims For Home Blood Testing
A microscope, a phone camera and a dash of quantum physics gave Oxford Immune Algorithmics’ Hector Zenil the idea for a new approach to longitudinal blood testing.
Medtech Insight - July 30, 2026

New Mucinex Product And VMS Brands Fuel Reckitt’s Self-Care Recovery
Reckitt's Self-Care category rebounded in Q2 and the company is now banking on the Mucinex 12HR launch and expansion in high-opportunity emerging markets to sustain the momentum.
HBW Insight - July 30, 2026

Samsung Bioepis’ Relaunched Lucentis Biosimilar Priced Above Originator
Samsung Bioepis' Byooviz (ranibizumab-nuna) has relaunched in the US at an average sales price of $1,190 – nearly four times its previous level and higher than both the originator Lucentis and rival biosimilar Cimerli.
Generics Bulletin - July 30, 2026

Pharma Is Spending More To Launch Less, And Scale Is No Longer The Answer
Norstella's new Pipeline-to-Patient Productivity Index finds R&D spend rising as output falls, yet the biggest spenders are not the winners. Beneath a GLP-1-inflated launch boom sits a portfolio-rejuvenation gap that could hollow out top-25 revenues by 2030.
In Vivo - July 30, 2026

Independent But Not Isolated: Shionogi Takes Long View On Fortified VC Activities
The corporate venture capital fund within the infectious disease-focused Japanese firm says it wants to keep an open mind and to provide long-term support for modalities and technologies that can be an “exciting fit" in 2040.
Scrip - July 30, 2026

Q&A: Preparing for California’s SB 54 Packaging Law
HBW Insight spoke with Alyssa Dizon of rePurpose Global about the challenges personal care packaging producers face as they work to comply with California's SB 54.
HBW Insight - July 30, 2026